845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade

Abstract

BackgroundABL503 (also known as TJ-L14B) is a bispecific antibody designed to simultaneously target PD-L1 and 4–1BB, and functions as both ‘PD-(L)1 inhibitor’ and ‘PD-L1-dependent 4–1BB agonist’, overcoming the known 4–1BB...